Deflatable bifurcated device

Information

  • Patent Grant
  • 8827954
  • Patent Number
    8,827,954
  • Date Filed
    Friday, June 5, 2009
    15 years ago
  • Date Issued
    Tuesday, September 9, 2014
    9 years ago
Abstract
A medical device for insertion and expansion within a bifurcated lumen is described. An expansion region of the device has regions thereon which, in some cases, enable the device to fold into a predetermined configuration upon deflation. The regions may be defined by differing modulus of the device material.
Description
TECHNICAL FIELD

This disclosure relates to the treatment of bifurcated lumens with a balloon.


BACKGROUND

The body includes various passageways including blood vessels such as arteries, and other body lumens. These passageways sometimes become occluded or weakened. For example, they can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is an artificial implant that is typically placed in a passageway or lumen in the body. Many endoprostheses are tubular members, examples of which include stents, stent-grafts, and covered stents.


Many endoprostheses can be delivered inside the body by a catheter. Typically the catheter supports a reduced-size or compacted form of the endoprosthesis as it is transported to a desired site in the body, for example, the site of weakening or occlusion in a body lumen. Upon reaching the desired site, the endoprosthesis is installed so that it can contact the walls of the lumen.


One method of installation involves expanding the endoprosthesis. The expansion mechanism used to install the endoprosthesis may include forcing it to expand radially. For example, the expansion can be achieved with a catheter that carries a balloon in conjunction with a balloon-expandable endoprosthesis reduced in size relative to its final form in the body. The balloon is inflated to deform and/or expand the endoprosthesis in order to fix it at a predetermined position in contact with the lumen wall. The balloon can then be deflated, and the catheter withdrawn.


Body lumens often include bifurcated regions with branching pathways. Treatments, such as angioplasty and stent delivery, are sometimes required at locations proximate the branching physiology. A balloon configured for use with a bifurcated endoprosthesis can have a non-linear portion that expands the bifurcated portion of the endoprosthesis. It is desirable that upon deflation, the balloon forms a predictable low profile configuration that facilitates withdrawal from the body and is not likely to become caught on the endoprosthesis during removal.


SUMMARY

The following summary is provided to facilitate an understanding of some of the innovative features unique to the present disclosure and is not intended to be a full description. A full appreciation of the disclosure can be gained by taking the entire specification, claims, drawings, and abstract as a whole.


In one embodiment, a medical device for treating a bifurcated lumen is described. The medical device may include a catheter shaft having a proximal region, a distal region, and a longitudinal axis. A main balloon may be disposed about the distal region of the catheter shaft along the longitudinal axis. A secondary balloon may be coupled to the distal region of the catheter shaft and may be disposed offset from the longitudinal axis. The secondary balloon may have an inflatable portion including a first section and a second section where the first section may be more flexible than the second section.


In another embodiment, a method of forming a medical device for treating a bifurcated lumen is described. The method may include providing a balloon system disposed about a distal region of a catheter shaft, the balloon system including a first inflatable portion along a longitudinal axis of the catheter shaft and a second inflatable portion offset from the longitudinal axis of the catheter shaft, and modifying a region of the second inflatable portion of the balloon system to form a first section and a second section in the second inflatable portion having varying crystallinity and/or thickness, wherein the first section is more flexible than the second section.


In yet another embodiment, a medical device for treating a bifurcated vessel is described. The medical device may include a catheter shaft having a proximal region and a distal region. A first balloon may be disposed about the distal region of the catheter shaft. A second balloon may be coupled to the distal region of the catheter shaft. The second balloon may include a first section and a second section forming a pattern where the first section being more flexible than the second section. The first section and the second section may cause the balloon to collapse into a predetermined configuration having one or more pleats.





BRIEF DESCRIPTION OF DRAWINGS

The invention may be more completely understood in consideration of the following detailed description of various illustrative embodiments of the disclosure in connection with the accompanying drawings, in which:



FIGS. 1A-1D are cross-sectional views illustrating delivery and deployment of a stent in a bifurcated lumen;



FIG. 2A is a cross-sectional view through a portion of a balloon catheter;



FIG. 2B is a perspective view illustrating a portion of a balloon catheter;



FIG. 3A is a side view of a balloon with ablated stripes in an inflated state;



FIGS. 3B and 3C are side and cross-sectional views of a balloon with ablated stripes in a collapsed state;



FIG. 4A is a side view of a balloon with stripes of increased crystallinity in an inflated state;



FIGS. 4B and 4C are side and cross-sectional views of a balloon with stripes of increased crystallinity in a collapsed state;



FIG. 5 is a schematic of a balloon being laser treated;



FIG. 6 is a scanning electron microscope image of a modified surface;



FIGS. 7-9 are alternative ablation or increased crystallinity patterns on inflated balloons; and



FIG. 10 is a perspective view of a balloon with ablated stripes.





DETAILED DESCRIPTION

The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.


Referring to FIGS. 1A-1D, a body lumen 10, such as a blood vessel, that has a bifurcated region 11 is treated with a catheter 12 carrying a stent 14 over an inflatable balloon system 15. At the bifurcated region 11, the body lumen 10 forms a first branch 16 and a second branch 18. Referring particularly to FIG. 1A, the catheter 12 may be delivered through a tortuous pathway over a guidewire 13 to the treatment site about the bifurcated region 11. Referring as well to FIGS. 1B and 1C, the balloon system 15 is expanded to expand the stent 14 into contact with the wall of the body lumen 10. Referring to FIG. 1D, the balloon system 15 is then deflated and the catheter 12 withdrawn, leaving the stent 14 in place.


The stent 14 is arranged such that it can be placed in the bifurcated region 11. In this embodiment, the stent 14 includes distal 20 and proximal 22 openings as well as a side opening 24 such that the stent 14 will not obstruct the second branch 18 when it is positioned to span the bifurcated region in the first branch 16. In addition, the stent 14 includes a main axis region 26 which is along the axis A (shown in FIG. 1D) of the stent 14 and is expanded into contact with the first branch 16 and an off-axis region 28 that is expanded into contact with the second branch 18. The balloon system 15 likewise includes a main axis region 30, for expanding the main axis 26 of the stent, and an off-axis region 32 that expands the off-axis region 28 of the stent.


Referring to FIGS. 2A and 2B, a cross section and perspective view, respectively, of the distal end of a balloon catheter 33 suitable for placement in a body lumen 16. As in, for example, FIGS. 1A and 1B, the catheter 33 includes an inner shaft 34 defining a guidewire lumen 36, an outer shaft 38, and a dual balloon system. The concentric inner and outer shafts define an annular lumen 37 through which inflation fluid can be directed to the balloon system. The dual balloon system has a first, main balloon 42 including a region 54 that inflates in a generally cylindrical profile along the axis B of the catheter to expand the stent in the first branch 16 of the lumen. The main balloon 42 also includes proximal and distal sleeves or waists 56, 58, that are attached to the catheter. The system also includes a second, off-axis balloon 44 that expands off the axis of the catheter into the second branch 18 of the lumen. The off-axis balloon 44 extends along and around a portion of the main balloon and includes a base portion 41, an apex or dome 43, and proximal and distal sleeves 51, 53. The proximal sleeves of both balloons are attached at a region 47 of outer shaft 38 and the distal sleeves of both balloons are attached to a distal region 49 of the inner shaft of the catheter. The proximal sleeve 51 or leg of the off-axis balloon 44 provides a pathway 50 for inflation fluid to the interior of the balloon 44. In some cases, the distal sleeve 53 of the balloon 44 may be sealed to prevent inflation fluid from passing substantially beyond the off axis inflatable portion of the balloon. In this embodiment, inflation fluid delivered through the lumen 37 is directed to the main and off-axis balloons so that the balloons are inflated substantially simultaneously. In other embodiments, the off-axis and main balloons are arranged sequentially along the catheter axis. In other embodiments, the off-axis and main balloons can be provided on separate catheters that are delivered simultaneously or sequentially. In other embodiments, a single balloon is provided that has main and off-axis inflatable regions. Exemplary stent and catheter arrangements are described in U.S. Patent Application Publication No. 2005/0102023, and in U.S. Pat. Nos. 6,325,826; 6,210,429; 6,706,062; 6,596,020; and 6,962,602, all of which are incorporated herein by reference in their entireties.


Referring to FIG. 3A an off-axis balloon 144 has flexible and less flexible portions. Specifically, the balloon 144 has regions 104 that are more flexible than the surrounding balloon material 120. Referring to FIGS. 3B and 3C, the more flexible regions 104 tend to fold inward upon deflation of the balloon 144.


Referring to FIG. 4A, a balloon 144′ has stiffer regions 114, as compared to the surrounding balloon material 120. Referring as well to FIGS. 4B and 4C, the stiffer regions 114 tend to stay on the outside of the balloon as it deflates and folds. The regions 104, 114 tend to stay on the outside of the balloon as it deflates and folds. The regions 104, 114 shown in FIGS. 3A et seq. and 4A et seq., respectively, form a pattern of stripes that are parallel to an axis C along which the distal sleeve 53 lies. A stripe pattern causes the dome of the balloon 114 to fold in an accordion manner, that is, the balloon 144 tends to form pleats as it collapses onto itself.


Referring to FIG. 5, the regions 104, 114 can be formed by treating the balloon material 120, such as by ablating or modifying the crystallinity of the balloon material by exposing the balloon to radiation, such as ultraviolet radiation. Ultraviolet radiation from a laser 30 can be modulated by controlled by a controller 32 to deliver selected energy to the exposed regions. For example, to ablate material the laser fluence is controlled to exceed the ablation threshold of the material. Chemical bonds are broken and the material is fractured into energetic fragments which leave the ablation zone. It is theorized that most of the energy is deposited in the ejected material so there is little thermal damage to surrounding materials. The high energy input to regions 104 removes some of the thickness of the material and therefore reduces the stiffness of these regions more than regions exposed to lower total energy or the unmodified polymer. The more flexible regions 104 tend to fold and collapse more readily as the balloon is deflated, forming valleys, as shown in FIGS. 3B and 3C.


To modify the crystallinity of the polymer without ablation, the laser fluence is controlled such that it is below the ablation threshold. In embodiments, the same laser 30 and controller 32 can be used to form regions 114 as used for forming regions 104. The regions 114 that are treated with the lower energy have increased crystallinity, which increases the stiffness or modulus of these regions. The increased stiffness causes the treated regions to be less flexible than the unmodified regions and thus the balloon is less likely to bend in the stiffer regions than in the unmodified regions. The stiffer regions 114 form the apexes of the accordion folds upon refolding as shown in FIGS. 4B and 4C. Whether the regions are ablated or have increased crystallinity, the balloon can have at least two modified regions. If the modified regions are in the form of stripes, the balloon can have two stripes or more, such as three stripes, as shown in FIGS. 3A and 4A, or even more stripes, such as four, five, size, seven or eight stripes. In embodiments, the balloon includes both regions 104, 114, e.g. in an alternating pattern.


The amount of ablation or degree of crystallinity modification can be selected to facilitate a desirable deflation profile. If the balloon is ablated, the amount of material removed can be for example, about 0.1-15%, such as 0.5 to 2.5% of the balloon wall thickness. If the balloon's crystallinity is modified without substantial ablation effects, the crystallinity of the polymer can be increased by about 2 to 90%, e.g., 2-5%, 5-10%, 10-20%, 20-40%, 40-60%, 60-70%, 70-80%, 80-90% or 20-80%, compared to the unmodified polymer. In some embodiments, the crystallinity percentage can be two, three or four times after modification than prior to modification. The thickness of the balloon in the crystallinity-modified regions and untreated regions can be substantially the same. With some materials, an increase in crystallinity is exhibited by nodules on the surface of the material. Crystallinity can be increased by heating the polymer material to between the glass transition temperature and the melt flow temperature. Within this temperature range, crystals begin to form, or crystals that were previously present grow larger. The amount of change in crystallinity can be controlled by controlling the energy delivered to the exposed regions, such as by controlling the time of exposure, the fluence and/or the wavelength of radiation. Crystallinity can be increased by increasing the exposure time at a low fluence. As noted above, the fluence threshold depends on the balloon material and on the type of wavelength of energy input into the material. Suitable UV lasers for treating the balloon have a wavelength between about 150-450 nm, such as 157, 193, 248, 308 or 351 nm. For treating a PET or a PEBAX® balloon with a 193 nm multigas laser, less than about 150 mJ/cm2, such as between about 60-70 mJ/cm2 will avoid ablating the balloon material. Other combinations of materials and lasers will have different thresholds of fluence to avoid ablation. Ultraviolet ablation is further described in U.S. Pat. No. 4,911,711. Suitable ablation and control systems are available from Coherent Lambda Physiks, in Goettingen, Germany. Crystallinity can be measured by WAX/SAX x-ray diffraction. Crystallinity measurements can be made at various vendors, such as the University of Minnesota Shepard characterization lab.


Crystallinity can be changed only on the surface or can be changed throughout the depth of the balloon wall. Suitable techniques for inputting heat into the balloon, such as UV lasers, affect primarily the surface of the balloon. For example, a UV laser may penetrate only part way into a polymer surface, such as 1-60 Angstroms into the balloon. Other heating techniques can penetrate more deeply into the material. With some methods of applying energy, the energy not only penetrates into the material, but radiates isotropically. This heating is considered to be massive or bulk heating of the material, because more than just the surface of the material is heated. A laser, such as a CO2 laser, an IR laser, a YAG laser, a diode laser, excimer laser, or any another suitable photon source, or a heat stick, i.e., a conductive material connected to a heat cartridge, or an RF generator can be used to apply heat to the balloon. In the case of an RF generator, a jelly having metal particles can be applied to the regions to be treated. If a laser is used to apply heat to the balloon, the balloon can be filled with a fluid to absorb the heat and prevent other portions of the balloon from being simultaneously treated. As noted herein, the amount of crystallinity can be controlled, such as by controlling the amount of time that energy is input into the balloon or controlling the energy output by the energy input device. To focus the heat on particular regions of the balloon, a mask can be used or the device for applying the heat can be focused only in the region where crystallization is desired. With some methods of treating the balloon, the depth of the crystallization can determine whether the treated region ends up on the apex or the valley of a fold. Surface treatment with a UV laser tends to form treated regions that are in the valleys of the folds of the balloon, where treatment with a CO2 laser or hot stick forms treated regions that are on the apex of the folds a balloon.


Flexibility or stiffness variations can also be created by other techniques, such as ion beam exposure and mechanically by cutting regions of the balloon wall. All of these techniques can be used in any combination to provide desired properties to the balloon. Ion beam treatment is further described in U.S. application Ser. No. 11/533,588, filed Sep. 20, 2006, and U.S. application Ser. No. 11/355,392, filed Feb. 16, 2006, both of which are incorporated herein by reference in their entirety. The treated regions can be formed by application of energy on the balloon directly or on a polymer tubular parison that is subsequently formed or blown into a balloon, e.g. by free inflation or blow molding. Balloon formation is described further in U.S. Pat. No. 4,963,313.


Referring to FIG. 6, an effect of some heat applications, such as application of UV laser, is to rearrange material at the surface of the balloon. A magnified view of a balloon surface that is crystallized using a UV laser shows nodules 52. The balloon is a TAXUS® Liberté™ OTW (PEBAX® 7233) polymer balloon available from Boston Scientific, Natick, Mass., and is exposed to UV radiation using a Lambda 210i, multigas UV excimer laser (available from Coherent Lambda Physiks, in Goettingen, Germany) operating at a wavelength of 193 nm with an attenuator set at 30 VA to achieve an output of 30 mJ/cm2. Forming the nodules 52 does not remove polymer material from the balloon wall, but rearranges the material on the balloon surface and can reduce the effective wall thickness between the nodules. A non-treated balloon wall would appear smooth and free of nodules. Nodules 52 are observed when the balloon is treated with a UV laser, but are not observed with other treatments, such as CO2 laser or hot stick. The UV laser treated regions also appear to be opaque, due to the surface modification.


Polymers suitable for forming the balloon include biaxially oriented polymers, thermoplastic elastomers, engineering thermoplastic elastomers, polyethylenes, polyethylene terephthalate (PET), polybutylenes, polyamides (e.g. nylon 66), polyether block amides (e.g., PEBAX®), polypropylene (PP), polystyrene (PS), polyvinyl chlorides (PVC), polytetrafluorethylene (PTFE), polymethylmethacrylate (PMMA), polyimide, polycarbonate (PC), polyisoprene rubber (PI), nitrile rubbers, silicone rubbers, ethylene-propylene diene rubbers (EPDM), butyl rubbers (BR), ethyl-ester thermoplastic elastomers (e.g., ARNITEL®), thermoplastic polyurethanes (PU) (e.g., those based on a glycol ether and an isocyanate, such as PELLETHANE®). In particular embodiments, a poly(ether-amide) block copolymer having the general formula




embedded image



in which PA represents a polyamide segment, e.g., nylon 12, and PE represents a polyether segment, e.g., poly(tetramethylene glycol) is utilized. Such polymers are commercially available from ARKEMA under the tradename PEBAX®. The balloon can be formed of single polymer or of multiple polymers, e.g. by coextrusion.


In addition to the linear treated regions described, the treated regions can be arranged in other configurations to enhance refolding. In some embodiments, the treated regions spiral around the dome of the balloon, so that the spiral winds around an axis that is perpendicular to the axis along which the sleeves extend. The spiral region can be one continuous region or can be series of non-contiguous regions that generally are in a spiral pattern. Referring to FIG. 7, the treated regions are not formed in a contiguous line, but are formed as a series of dots 150, dashes or shapes which together determine where the balloon will fold upon deflation. Referring to FIG. 8, the treated regions 155 can form stripes that are at an angle to the axis C of the sleeves, such as at an angle between about 30° and 60°, for example a 45° angle to the axis. Referring to FIG. 9, the treated region 160 can be wider on one side of the dome, that is on a side closer to a proximal sleeve 51 than on the other side of the dome, that is, the side closer to the distal sleeve 53. Regardless of the pattern, between about 20% and 80% of the balloon's dome can be treated to create regions of greater or lesser flexibility, such as 50±5% can be treated. In embodiments, the width of the treated regions is about 2 mm or less, such as about 0.1 to 0.5 mm. In some embodiments, ablation is performed only on the portion of the dome closest to the sleeves and not on the apex of the dome. In some bifurcation balloons, the apex of the dome tends to be the thinnest portion of the dome, having a thickness of only a few ten thousandths of an inch. Therefore, in such balloons, ablation may be avoided in the very thin parts of the balloon. Crystallinity modification, however, can be performed on the balloon dome portions closest to the sleeves or can be also on the apex of the dome.


Referring to FIG. 10, a bifurcation balloon 170 with five parallel treated regions 172 is shown. The top of the dome 174 is free of treated regions 172. As the balloon 170 deflates, the sides of the dome will collapse into pleats, causing the deflated balloon 170 to reduce down to a predictable shape so that the balloon 170 can be more easily pulled through a lumen than a non-treated balloon in a collapsed state.


Treating selected portions of a bifurcated balloon cause a bifurcation balloon to collapse in a predictable way when the balloon is deflated. The collapsed state can be selected so that the balloon folds in a compact manner. The more compact the balloon is when collapsed, the easier it may be to remove the balloon from a lumen after the balloon inflation and deflation. Moreover, a more compactly folded balloon may be less likely to catch on an expanded stent upon removal. Unlike cylindrical balloons, the bifurcation balloons tend to be in a naturally expanded state, even when they are not inflated. Thus, treating the balloons to enhance folding can add particular folding characteristics that the balloon would not otherwise have.


EXAMPLE

A 2.0×2.75 mm bifurcation PEBAX® polymer balloon made by Boston Scientific, Natick, Mass., is exposed to UV radiation using a Lambda LPX210i, multigas UV excimer laser (available from Coherent Lambda Physiks, in Goettingen, Germany) using an argon fluoride gas mixture operating at a pulse duration of 29 ns, a repetition rate of 25 Hz and at a wavelength of 193 nm with an attenuator set at 100% VA to deliver a fluence of 100 mJ/cm2, which is above the ablation threshold of PEBAX®, which is around 60-70 mJ/cm2. The homogenized beam from the laser is about 9 mm wide and about 9 mm long. Five parallel linear regions approximately 0.14 mm in width spaced equidistantly up the side of the dome of the balloon are exposed through a mask. Three of the regions are exposed at a shot spacing of 75 microns. Two of the regions are exposed at a shot spacing of 100 microns. The exposed regions became opaque.


Embodiments may include one or more of the following advantages. Balloon treatment of bifurcated lumens can be facilitated by reducing the likelihood that the balloon fold into a predictable configuration upon deflation. The profile of the side branch balloon on deflation after angioplasty or stent delivery can be reduced, e.g. by folding or forming into a desired, predictable configuration that facilitates withdrawal from a body lumen. It can require less withdrawal force to remove a balloon that has been folded compactly from a lumen than to remove a similar balloon that has not been folded compactly from the same lumen.


A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. The invention's scope is, of course, defined in the language in which the appended claims are expressed.

Claims
  • 1. A method of forming a medical device for treating a bifurcated lumen, the method comprising: providing a balloon system disposed about a distal region of a catheter shaft, the balloon system including a first inflatable portion along a longitudinal axis of the catheter shaft and a second inflatable portion offset from the longitudinal axis of the catheter shaft, the second inflatable portion of including a polymer; andmodifying a region of the second inflatable portion of the balloon system to form a first section and a second section in the second inflatable portion, the second section having a greater crystallinity than the first section such that the first section is more flexible than the second section, wherein the second inflatable portion includes a plurality of alternating first and second sections forming a striped pattern, wherein the second section stripes have a width of about 0.1 mm to about 0.5 mm, wherein the striped pattern is formed at an oblique angle to the longitudinal axis of the catheter shaft.
  • 2. The method of claim 1 wherein the modifying includes directing radiation at the region of the second inflatable portion.
  • 3. The method of claim 2 wherein directing radiation includes directing radiation that has a fluence below an ablation threshold to form the second section.
  • 4. The method of claim 2 wherein directing radiation includes directing radiation that has a fluence above an ablation threshold to form the first section.
  • 5. The method of claim 1 wherein the first section and second section cause the second inflatable portion to be collapsible into pleats.
  • 6. The method of claim 1 wherein the second inflatable portion includes a polymer and the first section is an ablation region.
  • 7. The method of claim 1, wherein the second section has a first width at a first side of the second inflatable portion and a second width at a second side of the second inflatable portion, the first width being greater than the second width.
  • 8. A medical device for treating a bifurcated vessel, the medical device comprising: a catheter shaft having a proximal region and a distal region and a longitudinal axis;a first balloon disposed about the distal region of the catheter shaft along the longitudinal shaft; anda second balloon coupled to the distal region of the catheter shaft and disposed offset from the longitudinal axis, the second balloon having an inflatable region including a plurality of sections, wherein alternating sections have different flexibility and/or stiffness such that one section is more flexible than adjacent sections and/or is stiffer than adjacent sections, wherein the plurality of sections form a pattern of alternating flexibility and/or stiffness;wherein the pattern of alternating flexibility and/or stiffness in the sections is a pattern of stripes at an oblique angle to the longitudinal axis, wherein the pattern of stripes causes the second balloon to collapse into a predetermined configuration having one or more pleats.
  • 9. The medical device of claim 8, wherein a first section is an ablation region and a second, adjacent section has a higher crystallinity than the first section.
  • 10. The medical device of claim 8, wherein the stripes are at an angle of between about 30 degrees and about 60 degrees from the longitudinal axis.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 61/059,243 filed on Jun. 5, 2008, the entire contents of which is hereby incorporated by reference. This application is related to U.S. application Ser. No. 11/599,049, filed Nov. 14, 2007, and U.S. application Ser. No. 12/479,611 filed on even date herewith, which claims the benefit of U.S. Provisional Application Ser. No. 61/059,250 field Jun. 5, 2008, the entire contents of all of which are hereby incorporated by reference.

US Referenced Citations (460)
Number Name Date Kind
1596754 Moschelle Aug 1926 A
3657744 Ersek Apr 1972 A
3872893 Roberts Mar 1975 A
4140126 Choudhury Feb 1979 A
4309994 Grunwald Jan 1982 A
4410476 Redding et al. Oct 1983 A
4413989 Schjeldahl et al. Nov 1983 A
4421810 Rasmussen Dec 1983 A
4453545 Inoue Jun 1984 A
4479497 Fogarty et al. Oct 1984 A
4503569 Dotter Mar 1985 A
4552554 Gould et al. Nov 1985 A
4681570 Dalton Jul 1987 A
4689174 Lupke Aug 1987 A
4731055 Melinyshyn et al. Mar 1988 A
4733665 Palmaz Mar 1988 A
4739662 Foote Apr 1988 A
4759748 Reed Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4769029 Patel Sep 1988 A
4819664 Nazari Apr 1989 A
4872874 Taheri Oct 1989 A
4878495 Grayzel Nov 1989 A
4896670 Crittenden Jan 1990 A
4900314 Quackenbush Feb 1990 A
4906244 Pinchuk et al. Mar 1990 A
4909258 Kuntz et al. Mar 1990 A
4911711 Telfair et al. Mar 1990 A
4941877 Montano, Jr. Jul 1990 A
4946464 Pevsner Aug 1990 A
4957501 Lahille et al. Sep 1990 A
4957508 Kaneko et al. Sep 1990 A
4963313 Noddin et al. Oct 1990 A
4964850 Bouton et al. Oct 1990 A
4983167 Sahota Jan 1991 A
4994071 MacGregor Feb 1991 A
5042976 Ishitsu et al. Aug 1991 A
5054501 Chuttani et al. Oct 1991 A
5059177 Towne et al. Oct 1991 A
5061240 Cherian Oct 1991 A
5064435 Porter Nov 1991 A
5085664 Bozzo Feb 1992 A
5102403 Alt Apr 1992 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5117831 Jang et al. Jun 1992 A
5122125 Deuss Jun 1992 A
5135536 Hillstead Aug 1992 A
5147317 Shank et al. Sep 1992 A
5147385 Beck et al. Sep 1992 A
5156785 Zdrahala Oct 1992 A
5159920 Condon et al. Nov 1992 A
5192297 Hull Mar 1993 A
5195970 Gahara Mar 1993 A
5195984 Schatz Mar 1993 A
5211683 Maginot May 1993 A
5217440 Frassica Jun 1993 A
5222971 Willard et al. Jun 1993 A
5226913 Pinchuk Jul 1993 A
5234457 Andersen Aug 1993 A
5236446 Dumon Aug 1993 A
5257974 Cox Nov 1993 A
5263932 Jang Nov 1993 A
5304220 Maginot Apr 1994 A
5306246 Sahatjian et al. Apr 1994 A
5320605 Sahota Jun 1994 A
5324257 Osborne et al. Jun 1994 A
5334153 McIntyre et al. Aug 1994 A
5337733 Bauerfeind et al. Aug 1994 A
5338300 Cox Aug 1994 A
5342295 Imran Aug 1994 A
5342297 Jang Aug 1994 A
5342387 Summers Aug 1994 A
5350395 Yock Sep 1994 A
5382472 Yanidis et al. Jan 1995 A
5383892 Cardon et al. Jan 1995 A
5387235 Chuter Feb 1995 A
5395332 Resseman et al. Mar 1995 A
5395334 Keith et al. Mar 1995 A
5404887 Prather Apr 1995 A
5409458 Khairkhahan et al. Apr 1995 A
5413581 Goy May 1995 A
5413586 Dibie et al. May 1995 A
5417208 Winkler May 1995 A
5425765 Tiefenbrun et al. Jun 1995 A
5437638 Bowman Aug 1995 A
5443497 Venbrux Aug 1995 A
5445624 Jimenez Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5449382 Dayton Sep 1995 A
5456666 Campbell et al. Oct 1995 A
5456694 Marin et al. Oct 1995 A
5456712 Maginot Oct 1995 A
5456714 Owen Oct 1995 A
5458572 Campbell et al. Oct 1995 A
5458605 Klemm Oct 1995 A
5462530 Jang Oct 1995 A
5476471 Shifrin et al. Dec 1995 A
5489271 Andersen Feb 1996 A
5489295 Piplani et al. Feb 1996 A
5496292 Burnham Mar 1996 A
5505702 Arney Apr 1996 A
5507768 Lau et al. Apr 1996 A
5507769 Marin et al. Apr 1996 A
5514154 Lau et al. May 1996 A
5514178 Torchio May 1996 A
5522801 Wang Jun 1996 A
5531788 Dibie et al. Jul 1996 A
5545132 Fagan et al. Aug 1996 A
5549553 Ressemann et al. Aug 1996 A
5549554 Miraki Aug 1996 A
5562620 Klein et al. Oct 1996 A
5562724 Vorwerk et al. Oct 1996 A
5562725 Schmitt et al. Oct 1996 A
5562726 Chuter Oct 1996 A
5569295 Lam Oct 1996 A
5571087 Ressemann et al. Nov 1996 A
5575771 Walinsky Nov 1996 A
5575817 Martin Nov 1996 A
5575818 Pinchuk Nov 1996 A
5591228 Edoga Jan 1997 A
5593442 Klein Jan 1997 A
5607444 Lam Mar 1997 A
5609605 Marshall et al. Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5609629 Fearnot et al. Mar 1997 A
5613949 Miraki Mar 1997 A
5613980 Chauhan Mar 1997 A
5613981 Boyle et al. Mar 1997 A
5617878 Taheri Apr 1997 A
5626600 Horzewski et al. May 1997 A
5628788 Pinchuk May 1997 A
5632762 Myler May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5634902 Johnson et al. Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5643340 Nunokawa Jul 1997 A
5653743 Martin Aug 1997 A
5662614 Edoga Sep 1997 A
5669924 Shaknovich Sep 1997 A
5669932 Fischell et al. Sep 1997 A
5674197 van Muiden et al. Oct 1997 A
5676696 Marcade Oct 1997 A
5676697 McDonald Oct 1997 A
5679400 Tuch Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690642 Osborne et al. Nov 1997 A
5693084 Chuter Dec 1997 A
5693086 Goicoechea et al. Dec 1997 A
5693088 Lazarus Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5707354 Salmon et al. Jan 1998 A
5709713 Evans et al. Jan 1998 A
5716365 Goicoechea et al. Feb 1998 A
5716617 Khandke et al. Feb 1998 A
5718683 Ressemann et al. Feb 1998 A
5718724 Goicoechea et al. Feb 1998 A
5720735 Dorros Feb 1998 A
5723004 Dereume et al. Mar 1998 A
5724977 Yock et al. Mar 1998 A
5728158 Lau et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5735893 Lau et al. Apr 1998 A
5746766 Edoga May 1998 A
5749825 Fischell et al. May 1998 A
5749848 Jang et al. May 1998 A
5755734 Richter et al. May 1998 A
5755735 Richter et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755771 Penn et al. May 1998 A
5755778 Kleshinski May 1998 A
5759172 Weber et al. Jun 1998 A
5762631 Klein Jun 1998 A
5776101 Goy Jul 1998 A
5776161 Globerman Jul 1998 A
5776180 Goicoechea et al. Jul 1998 A
5782906 Marshall et al. Jul 1998 A
5797947 Mollenauer Aug 1998 A
5800450 Lary et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5814061 Osborne et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824008 Bolduc et al. Oct 1998 A
5824036 Lauterjung Oct 1998 A
5824040 Cox et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824044 Quiachon et al. Oct 1998 A
5827320 Richter et al. Oct 1998 A
5833650 Imran Nov 1998 A
5836966 St. Germain Nov 1998 A
5837008 Berg et al. Nov 1998 A
5838856 Lee Nov 1998 A
5843031 Hermann et al. Dec 1998 A
5843160 Rhodes Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5846204 Solomon Dec 1998 A
5851210 Torossian Dec 1998 A
5851464 Davila et al. Dec 1998 A
5853389 Hijlkema Dec 1998 A
5855600 Alt Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5865178 Yock Feb 1999 A
5868777 Lam Feb 1999 A
5871536 Lazarus Feb 1999 A
5871537 Holman et al. Feb 1999 A
5891133 Murphy-Chutorian Apr 1999 A
5897588 Hull et al. Apr 1999 A
5906640 Penn et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5913895 Burpee et al. Jun 1999 A
5913897 Corso, Jr. et al. Jun 1999 A
5921958 Ressemann et al. Jul 1999 A
5922020 Klein et al. Jul 1999 A
5928248 Acker Jul 1999 A
5938682 Hojeibane et al. Aug 1999 A
5938696 Goicoecchea et al. Aug 1999 A
5948016 Jang Sep 1999 A
5951599 McCrory Sep 1999 A
5961548 Shmulewitz Oct 1999 A
5967986 Cimochowski et al. Oct 1999 A
5972018 Israel et al. Oct 1999 A
6007517 Anderson Dec 1999 A
6013054 Jiun Yan Jan 2000 A
6013091 Ley et al. Jan 2000 A
6017324 Tu et al. Jan 2000 A
6017363 Hojeibane Jan 2000 A
6024763 Lenker et al. Feb 2000 A
6030414 Taheri Feb 2000 A
6033434 Borghi Mar 2000 A
6033435 Penn et al. Mar 2000 A
6036682 Lange et al. Mar 2000 A
6039749 Marin et al. Mar 2000 A
6042597 Kveen et al. Mar 2000 A
6045557 White et al. Apr 2000 A
6048361 Von Oepen Apr 2000 A
6056775 Borghi et al. May 2000 A
6059823 Holman et al. May 2000 A
6059824 Taheri May 2000 A
6066168 Lau et al. May 2000 A
6068655 Seguin et al. May 2000 A
6071285 Lashinski et al. Jun 2000 A
6086611 Duffy et al. Jul 2000 A
6090127 Globerman Jul 2000 A
6090128 Douglas Jul 2000 A
6090133 Richter et al. Jul 2000 A
6096073 Webster et al. Aug 2000 A
6099497 Adams et al. Aug 2000 A
6117117 Mauch Sep 2000 A
6117156 Richter et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129738 Lashinski et al. Oct 2000 A
6129754 Kanesaka et al. Oct 2000 A
6142973 Carleton et al. Nov 2000 A
6152945 Bachinski et al. Nov 2000 A
6165195 Wilson et al. Dec 2000 A
6165197 Yock Dec 2000 A
6165214 Lazarus Dec 2000 A
6179867 Cox Jan 2001 B1
6183506 Penn et al. Feb 2001 B1
6183509 Dibie Feb 2001 B1
6190403 Fischell et al. Feb 2001 B1
6193746 Strecker Feb 2001 B1
6203569 Wijay Mar 2001 B1
6210380 Mauch Apr 2001 B1
6210429 Vardi et al. Apr 2001 B1
6217527 Selmon et al. Apr 2001 B1
6217608 Penn et al. Apr 2001 B1
6221080 Power Apr 2001 B1
6221090 Wilson Apr 2001 B1
6221098 Wilson et al. Apr 2001 B1
6231563 White et al. May 2001 B1
6231598 Berry et al. May 2001 B1
6231600 Zhong May 2001 B1
6235051 Murphy May 2001 B1
6241762 Shanley Jun 2001 B1
6258073 Mauch Jul 2001 B1
6258099 Mariero et al. Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6258121 Yang et al. Jul 2001 B1
6261273 Ruiz Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261319 Kveen et al. Jul 2001 B1
6264682 Wilson et al. Jul 2001 B1
6273911 Cox et al. Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6287314 Lee et al. Sep 2001 B1
6290673 Shanley Sep 2001 B1
6293967 Shanley Sep 2001 B1
6299634 Bergeron Oct 2001 B1
6302906 Goicoecchea et al. Oct 2001 B1
6309412 Lau et al. Oct 2001 B1
6309414 Rolando et al. Oct 2001 B1
6312459 Huang et al. Nov 2001 B1
6325821 Gaschino et al. Dec 2001 B1
6325826 Vardi et al. Dec 2001 B1
6334870 Ehr et al. Jan 2002 B1
6346089 Dibie Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6355060 Lenker et al. Mar 2002 B1
6358266 Bonutti Mar 2002 B1
6361544 Wilson et al. Mar 2002 B1
6361555 Wilson Mar 2002 B1
6371978 Wilson Apr 2002 B1
6383213 Wilson et al. May 2002 B2
6383215 Sass May 2002 B1
6387120 Wilson et al. May 2002 B2
6395018 Castaneda May 2002 B1
6398792 O'Connor Jun 2002 B1
6398804 Spielberg Jun 2002 B1
6428567 Wilson et al. Aug 2002 B2
6428568 Gaudoin et al. Aug 2002 B2
6428570 Globerman Aug 2002 B1
6432133 Lau et al. Aug 2002 B1
6436104 Hojeibane Aug 2002 B2
6436134 Richter et al. Aug 2002 B2
6468302 Cox et al. Oct 2002 B2
6475208 Mauch Nov 2002 B2
6478816 Kveen et al. Nov 2002 B1
6482211 Choi Nov 2002 B1
6485511 Lau et al. Nov 2002 B2
6494905 Zedler et al. Dec 2002 B1
6508836 Wilson et al. Jan 2003 B2
6511504 Lau et al. Jan 2003 B1
6511505 Cox et al. Jan 2003 B2
6520988 Colombo et al. Feb 2003 B1
6527799 Shanley Mar 2003 B2
6540719 Bigus et al. Apr 2003 B2
6540779 Richter et al. Apr 2003 B2
6572647 Supper et al. Jun 2003 B1
6579309 Loos et al. Jun 2003 B1
6579312 Wilson et al. Jun 2003 B2
6582394 Reiss et al. Jun 2003 B1
6582459 Lau et al. Jun 2003 B1
6596020 Vardi et al. Jul 2003 B2
6596022 Lau et al. Jul 2003 B2
6599315 Wilson Jul 2003 B2
6599316 Vardi et al. Jul 2003 B2
6602284 Cox et al. Aug 2003 B2
6641609 Globerman Nov 2003 B2
6645241 Strecker Nov 2003 B1
6652573 Von Oepen Nov 2003 B2
6669717 Marotta et al. Dec 2003 B2
6676667 Mariero et al. Jan 2004 B2
6679911 Burgermeister Jan 2004 B2
6689156 Davidson et al. Feb 2004 B1
6692483 Vardi et al. Feb 2004 B2
6695877 Brucker et al. Feb 2004 B2
6706062 Vardi et al. Mar 2004 B2
6709440 Callol et al. Mar 2004 B2
6736841 Musbach et al. May 2004 B2
6770092 Richter Aug 2004 B2
6780174 Mauch Aug 2004 B2
6802856 Wilson Oct 2004 B2
6827735 Greenberg Dec 2004 B2
6827736 Perouse Dec 2004 B2
6835203 Vardi et al. Dec 2004 B1
6852124 Cox et al. Feb 2005 B2
6855125 Shanley Feb 2005 B2
6890349 McGukin, Jr. et al. May 2005 B2
6908477 McGukin, Jr. et al. Jun 2005 B2
6942689 Majercak Sep 2005 B2
6962602 Vardi et al. Nov 2005 B2
6989025 Burgmeier et al. Jan 2006 B2
7004963 Wang et al. Feb 2006 B2
7056323 Mariero et al. Jun 2006 B2
7105019 Hojeibane Sep 2006 B2
7118593 Davidson et al. Oct 2006 B2
7125419 Sequin et al. Oct 2006 B2
7163553 Limon Jan 2007 B2
7220275 Davidson et al. May 2007 B2
7238197 Sequin et al. Jul 2007 B2
7244853 Schreiber et al. Jul 2007 B2
7252679 Fischell et al. Aug 2007 B2
7344557 Yadin Mar 2008 B2
7387639 Bourang et al. Jun 2008 B2
7585317 Davidson et al. Sep 2009 B2
20010012927 Mauch Aug 2001 A1
20010016767 Wilson et al. Aug 2001 A1
20010016768 Wilson et al. Aug 2001 A1
20010027291 Shanley Oct 2001 A1
20010027338 Greenberg Oct 2001 A1
20010029396 Wilson et al. Oct 2001 A1
20010037116 Wilson et al. Nov 2001 A1
20010037138 Wilson et al. Nov 2001 A1
20010037140 Gaudoin et al. Nov 2001 A1
20010037146 Lau et al. Nov 2001 A1
20010037147 Lau et al. Nov 2001 A1
20010039395 Mariero et al. Nov 2001 A1
20010039448 Dibie Nov 2001 A1
20010041927 Solem Nov 2001 A1
20010047201 Cox et al. Nov 2001 A1
20010049552 Richter et al. Dec 2001 A1
20010056297 Hojeibane Dec 2001 A1
20020013618 Marotta et al. Jan 2002 A1
20020013619 Shanley Jan 2002 A1
20020022874 Wilson Feb 2002 A1
20020026232 Marotta et al. Feb 2002 A1
20020032478 Boekstegers et al. Mar 2002 A1
20020035392 Wilson Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020052648 McGukin, Jr. et al. May 2002 A1
20020058990 Jang May 2002 A1
20020072790 McGuckin, Jr. et al. Jun 2002 A1
20020107564 Cox et al. Aug 2002 A1
20020111675 Wilson Aug 2002 A1
20020123790 White et al. Sep 2002 A1
20020123797 Majercak Sep 2002 A1
20020123798 Burgermeister Sep 2002 A1
20020151959 Von Oepen Oct 2002 A1
20020156516 Vardi et al. Oct 2002 A1
20020156517 Perouse Oct 2002 A1
20020165604 Shanley Nov 2002 A1
20020173835 Bourang et al. Nov 2002 A1
20020173840 Brucker et al. Nov 2002 A1
20020177892 Globerman Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020193872 Trout, III et al. Dec 2002 A1
20020193873 Brucker et al. Dec 2002 A1
20030004535 Musbach et al. Jan 2003 A1
20030009209 Hojeibane Jan 2003 A1
20030009214 Shanley Jan 2003 A1
20030014102 Hong et al. Jan 2003 A1
20030023301 Cox et al. Jan 2003 A1
20030028211 Crocker et al. Feb 2003 A1
20030050688 Fischell et al. Mar 2003 A1
20030055378 Wang et al. Mar 2003 A1
20030074047 Richter Apr 2003 A1
20030093109 Mauch May 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114915 Mariero et al. Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125799 Limon Jul 2003 A1
20030125802 Callol et al. Jul 2003 A1
20030144683 Sirhan et al. Jul 2003 A1
20030163148 Wang et al. Aug 2003 A1
20040015227 Vardi et al. Jan 2004 A1
20040072849 Schreiber et al. Apr 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040133223 Weber Jul 2004 A1
20040133268 Davidson et al. Jul 2004 A1
20040138737 Davidson et al. Jul 2004 A1
20040148006 Davidson et al. Jul 2004 A1
20040225318 Eidenschink et al. Nov 2004 A1
20050015046 Weber et al. Jan 2005 A1
20050015108 Williams et al. Jan 2005 A1
20050027344 Eidenschink Feb 2005 A1
20050060027 Khenansho et al. Mar 2005 A1
20050102019 Yadin May 2005 A1
20050102023 Yadin et al. May 2005 A1
20050177130 Konstantino et al. Aug 2005 A1
20060182873 Klisch et al. Aug 2006 A1
20070067018 Miller Mar 2007 A1
20070191923 Weber et al. Aug 2007 A1
20080097302 Chen Apr 2008 A1
20080109060 Yadin May 2008 A1
20080114294 Holman et al. May 2008 A1
20080125706 Sutermeister et al. May 2008 A1
20080243221 Arcand Oct 2008 A1
Foreign Referenced Citations (69)
Number Date Country
2318314 Jul 1999 CA
9014845.2 Jan 1991 DE
29701758 Mar 1997 DE
0551179 Jul 1993 EP
0646365 Apr 1995 EP
0684022 Nov 1995 EP
0804907 Nov 1997 EP
0876805 Nov 1998 EP
0884028 Dec 1998 EP
0891751 Jan 1999 EP
0897698 Feb 1999 EP
0897700 Feb 1999 EP
0904745 Mar 1999 EP
1031328 Aug 2000 EP
1031330 Aug 2000 EP
1157674 Nov 2001 EP
1254644 Nov 2002 EP
2678508 Jan 1993 FR
WO 8806026 Aug 1988 WO
WO 9013332 Nov 1990 WO
WO 9112779 Sep 1991 WO
WO 9219308 Nov 1992 WO
WO 9426180 Nov 1994 WO
WO 9508965 Apr 1995 WO
WO 9521592 Aug 1995 WO
WO 9629955 Oct 1996 WO
WO 9641592 Dec 1996 WO
WO 9709946 Mar 1997 WO
WO 9716217 May 1997 WO
WO 9726936 Jul 1997 WO
WO 9732544 Sep 1997 WO
WO 9733532 Sep 1997 WO
WO 9741803 Nov 1997 WO
WO 9745073 Dec 1997 WO
WO 9817204 Apr 1998 WO
WO 9819628 May 1998 WO
WO 9835634 Aug 1998 WO
WO 9836709 Aug 1998 WO
WO 9837833 Sep 1998 WO
WO 9844871 Oct 1998 WO
WO 9848733 Nov 1998 WO
WO 9852497 Nov 1998 WO
WO 9915103 Apr 1999 WO
WO 9917680 Apr 1999 WO
WO 9924104 May 1999 WO
WO 9934749 Jul 1999 WO
WO 9936002 Jul 1999 WO
WO 9939661 Aug 1999 WO
WO 9958059 Nov 1999 WO
WO 9965419 Dec 1999 WO
WO 0000104 Jan 2000 WO
WO 0012166 Mar 2000 WO
WO 0013613 Mar 2000 WO
WO 0053122 Sep 2000 WO
WO 0074595 Dec 2000 WO
WO 0121095 Mar 2001 WO
WO 0121109 Mar 2001 WO
WO 0121244 Mar 2001 WO
WO 0170299 Sep 2001 WO
WO 02068012 Sep 2002 WO
WO 02076333 Oct 2002 WO
WO 02094336 Nov 2002 WO
WO 03055414 Jul 2003 WO
WO 2004026180 Apr 2004 WO
WO 2005046757 May 2005 WO
WO 2005122958 Dec 2005 WO
2006014631 Feb 2006 WO
WO 2006053106 May 2006 WO
2008024220 Feb 2008 WO
Non-Patent Literature Citations (14)
Entry
U.S. Appl. No. 12/479,611 to Richard A. Noddin et al., filed Jun. 5, 2009.
Caputo et al., “Stent Jail: A Minimum-Security Prison,” The American Journal of Cardiology, vol. 77, pp. 1226-1230, Jun. 1, 1996.
Carrie et al., “‘T’-Shaped Stent Placement: A Technique for the Treatment of Dissected Bifurcation Lesions,” Catheterization and Cardiovascular Diagnosis, vol. 37, pp. 311-313, 1996.
Chevalier et at., “Placement of Coronary Stents in Bifurcation Lesions by the ‘Culotte’ Technique,” The American Journal of Cardiology, vol. 82, pp. 943-949, Oct. 15, 1998.
Colombo et al., “‘Kissing’ Stents for Bifurcational Coronary Lesion,” Catheterization and Cardiovascular Diagnosis, vol. 30, pp. 327-330, 1993.
Dichek et al., “Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells,” Circulation,vol. 80, No. 5, pp. 1347-1353, Nov. 1989.
Fischman et al., “A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease,” New England Journal of Medicine, vol. 331, No. 8, pp. 496-501, Aug. 25, 1994.
Katoh et al., “New Double Wire Technique to Stent Ostial Lesions,” Catheterization and Cardiovascular Diagnosis, vol. 40, pp. 400-402, 1997.
“Laser”, Wikipedia, the free encyclopedia, http://en.wikipedia.org./wiki/Laser, printed Mar. 21, 2006, 11 pages.
Lewis et al., “Acute Procedural Results in the Treatment of 30 Coronary Artery Bifurcation Lesions with a Double-Wire Atherectomy Technique for Side-Branch Protection,” American Heart Journal, vol. 127, No. 6, pp. 1600-1607, 1994.
Nakamura et al., “Techniques for Palmaz-Schatz Stent Deployment in Lesions with a Large Side Branch,” Catheterization and Cardiovascular Diagnosis, vol. 34, pp. 353-361, 1995.
Satler et al. “Bifurcation Disease: To Treat or Not to Treat,” Catheterization and Cardiovascular Interventions, vol. 50, pp. 411-412, 2000.
Serruys et al., “A Comparison of Balloon Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease,” The New England Journal of Medicine, vol. 331, No. 8, pp. 489-495, Aug. 25, 1994.
Yamashita et al., “Bifurcation Lesions: Two Stents Versus One Stent—Immediate and Follow-up Results,” Journal of the American College of Cardiology, vol. 35, No. 5, pp. 1145-1151, Apr. 2000.
Related Publications (1)
Number Date Country
20100114019 A1 May 2010 US
Provisional Applications (1)
Number Date Country
61059243 Jun 2008 US